SCHEMBL2749288

SCHEMBL2749288

Cc1ccc(C(F)(F)F)c(N(S)C(N)=O)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.36
AKR1C2 P52895 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
MAPT P10636 2/20 0.34
RAB9A P51151 2/20 0.34
TP53 P04637 2/20 0.34
CES2 O00748 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SCN9A Q15858 3/20 0.33
ALDH1A1 P00352 1/20 0.32
ALOX12 P18054 1/20 0.32
PTK2 Q05397 1/20 0.32
KIF11 P52732 1/20 0.32
NOTUM Q6P988 1/20 0.32
ALOX5 P09917 1/20 0.32
PARP1 P09874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14053642 0.77 LMNA (0.40) MEN1KMT2ASCN9AALDH1A1
SCHEMBL4199227 0.75 TDP1 (0.38) SMN1; SMN2MAPTRAB9ATP53MEN1
SCHEMBL6114258 0.73 HPGD (0.51) MAPTMEN1KMT2AALDH1A1
SCHEMBL20457524 0.72 ACP1 (0.36) SMN1; SMN2ALDH1A1KIF11NOTUM
SCHEMBL3607811 0.72 EPHX2 (0.43) AKR1C3AKR1C2SMN1; SMN2MAPTNPSR1
SCHEMBL16404629 0.71 CES2 (0.46) AKR1C3AKR1C2SMN1; SMN2MAPTRAB9A
SCHEMBL30087617 0.70 SMN1; SMN2 (0.42) AKR1C3AKR1C2SMN1; SMN2MAPTRAB9A
SCHEMBL4620600 0.68 CES2 (0.46) AKR1C3AKR1C2SMN1; SMN2MAPTRAB9A
SCHEMBL28214649 0.68 ICMT (0.40) AKR1C3AKR1C2SMN1; SMN2MAPTRAB9A
SCHEMBL27827977 0.67 CES2 (0.48) AKR1C3AKR1C2SMN1; SMN2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 AKR1C3 1360/4885AKR1C2 852/4885SMN1; SMN2 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.